Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $65.00

Key Points

• Stifel Nicolaus raised Dianthus Therapeutics' price target from $52.00 to $65.00, indicating a potential upside of 78.11% from its previous close.
• Multiple analysts have given Dianthus a "buy" rating, with a consensus target price of $61.57, reflecting strong interest in the stock.
• The company's CFO sold 20,000 shares at an average price of $35.00, amounting to a total transaction of $700,000.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) had its price target increased by Stifel Nicolaus from $52.00 to $65.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' target price indicates a potential upside of 78.11% from the company's previous close.

DNTH has been the subject of several other research reports. Raymond James Financial restated an "outperform" rating and set a $63.00 price objective (up previously from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday. Wedbush boosted their price objective on Dianthus Therapeutics from $42.00 to $44.00 and gave the stock an "outperform" rating in a research report on Friday. William Blair began coverage on Dianthus Therapeutics in a research report on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Guggenheim upped their price target on Dianthus Therapeutics from $92.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday. Nine equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $61.57.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH traded down $1.37 during trading hours on Friday, hitting $36.50. The company's stock had a trading volume of 102,645 shares, compared to its average volume of 387,335. The stock has a fifty day simple moving average of $22.65 and a 200-day simple moving average of $20.43. The company has a market capitalization of $1.17 billion, a P/E ratio of -11.23 and a beta of 1.46. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $38.59.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. On average, equities analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Ryan Savitz sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 8.15% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vestal Point Capital LP boosted its stake in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock worth $59,616,000 after buying an additional 1,499,931 shares during the last quarter. RA Capital Management L.P. increased its holdings in shares of Dianthus Therapeutics by 53.6% in the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock worth $52,003,000 after purchasing an additional 1,000,333 shares during the last quarter. Octagon Capital Advisors LP increased its holdings in shares of Dianthus Therapeutics by 11.0% in the first quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock worth $42,478,000 after purchasing an additional 231,500 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Dianthus Therapeutics by 14.5% in the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock worth $21,887,000 after purchasing an additional 149,200 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in Dianthus Therapeutics by 14.4% during the fourth quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company's stock worth $23,607,000 after acquiring an additional 136,314 shares during the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.